SCHEMBL167645

SCHEMBL167645

CN(C)CCc1cn(-c2ccc(F)cc2)nc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.49
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46
AGTR1 P30556 1/20 0.43
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
SSTR5 P35346 2/20 0.38
HTR1F P30939 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MPO P05164 1/20 0.36
HTR7 P34969 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
P2RX7 Q99572 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15412735 0.89 NPC1 (0.45) KMT2ANPC1LMNARAB9AAGTR1
SCHEMBL168425 0.84 NPC1 (0.65) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL27904129 0.76 TAAR1 (0.41) KMT2ANPC1LMNARAB9AAGTR1
SCHEMBL398111 0.75 KMT2A (0.59) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL168035 0.72 AURKA (0.41) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL167729 0.71 KMT2A (0.55) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL176297 0.71 NPC1 (0.57) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL168920 0.71 NPC1 (0.46) KMT2ANPC1LMNARAB9AKDM4E
SCHEMBL22923912 0.70 LMNA (0.42) KMT2ALMNAKDM4EL3MBTL1TAAR1
SCHEMBL167649 0.70 NPC1 (0.45) KMT2ANPC1LMNARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103124729-B As the pharmaceutical active compounds of Axl inhibitor LEAD DISCOVERY CENTER GMBH (DE) 2016-01-20 CN disclosed
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 EP disclosed
CN-103124729-A Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH 2013-05-29 CN disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 KMT2A 1175/4885NPC1 3417/4885LMNA 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.